Modality
Multispecific
MOA
FGFRi
Target
FXIa
Pathway
Checkpoint
CLLThymomaRB
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Jan 2031
Phase 1Current
NCT04843050
312 pts·RB
2023-04→2027-09·Terminated
NCT06826964
2,418 pts·RB
2018-03→2031-01·Terminated
2,730 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-01-103mo agoPDUFA· RB
2026-10-026mo awayConference· Thymoma
2027-09-241.5y awayPh2 Data· RB
2031-01-254.8y awayPh2 Data· RB
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Termina…
P1/2
Termina…
Catalysts
PDUFA
2026-01-10 · 3mo ago
RB
Conference
2026-10-02 · 6mo away
Thymoma
Ph2 Data
2027-09-24 · 1.5y away
RB
Ph2 Data
2031-01-25 · 4.8y away
RB
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04843050 | Phase 1/2 | RB | Terminated | 312 | DAS28 |
| NCT06826964 | Phase 1/2 | RB | Terminated | 2418 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| BII-5449 | Biogen | Phase 3 | FXIa |